Next steps for AI in healthcare

It will bring together stakeholders and policymakers to discuss the future of AI in the NHS in light of ambitions in the 10 Year Health Plan for the NHS to be the most AI-enabled healthcare system in the world. The agenda will consider opportunities for innovation and growth, alongside priorities for safety and an evidence-based approach, as well as questions around workforce capabilities, equity and public confidence.

Use cases & integration

There will be discussion on enabling AI use cases in precision medicine, guidance through the NHS App, and deployment to ease administrative burdens. Planned sessions will assess next steps for integrating AI across the NHS, public trust and awareness, workforce education, and maintaining patient safety and quality of care whilst developing automation and improving efficiency.

Regulation & oversight

Priorities for regulation will be examined, as a National Commission into the Regulation of AI in Healthcare is appointed to review existing arrangements and to recommend a new framework. Delegates will consider how regulatory gaps can be addressed and how innovation can be encouraged while maintaining safety, consistency and public confidence - looking at emerging technologies such as ambient voice systems, and commitments in the Life Sciences Sector Plan.

Further planned sessions focus on requirements for human oversight of automated decision-making and how these may affect the design of AI-assisted triage and eligibility assessments. Discussion will look at the development of the Health Data Research Service and its role in facilitating secure access and linkage, and ongoing collaboration with the Regulatory Innovation Office on drug discovery and device pathways. Delegates will consider how these developments influence international regulatory alignment, investment, and the UK’s wider health-data research infrastructure.

Scalability, data & research

Delegates will assess initiatives from MHRA, NICE and NHS England in supporting the safe scaling of diagnostic AI tools, developing new approval routes for market access, and implications for investment confidence and sector growth. Further discussion will examine data use and governance in light of the Data (Use and Access) Act 2025, and priorities for research collaboration, such as enabling more flexible consent regimes, supporting broader clinical trials, and ensuring that governance arrangements maintain public confidence.